Thoracic malignancies, cisplatin and renal function

European Respiratory Journal

Volumn 37, Issue 4, 2011, Pages 760-761

  Nortier, J ^a   Sculier, J P ^b  

^a ERASME HOSPITAL   (Belgium)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; IFOSFAMIDE; MITOMYCIN;

ALBUMINURIA; CHRONIC KIDNEY DISEASE; COMORBIDITY; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EDITORIAL; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INTERSTITIAL NEPHRITIS; KIDNEY FUNCTION; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MESOTHELIOMA; NEPHROTOXICITY; NEUROTOXICITY; PREVALENCE; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT RESPONSE; URINARY EXCRETION;

EID: 79953720566     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00160810     Document Type: Editorial

References (19)

1. Rossof AH, Bearden JD III, Coltman CA Jr. Phase II evaluation of cis-diamminedichloroplatinum(II) in lung cancer. Cancer Treat Rep 1976; 60: 1679-1680. (Pubitemid 8059971)
2. Sculier JP, Moro-Sibilot D. First- and second-line therapy for advanced nonsmall cell lung cancer. Eur Respir J 2009; 33: 915-930.
3. Auperin A, Le PC, Pignon JP, et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol 2006; 17: 473-483. (Pubitemid 43329586)
4. Berghmans T, Paesmans M, Meert AP, et al. Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer 2005; 49: 13-23. (Pubitemid 40798089)
5. Mascaux C, Paesmans M, Berghmans T, et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 2000; 30: 23-36.
6. Pujol JL, Carestia L, Daures JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 2000; 83: 8-15.
7. Berghmans T, Paesmans M, Lalami Y, et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 2002; 38: 111-121. (Pubitemid 35157753)
8. Scherpereel A, Astoul P, Baas P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 2010; 35: 479-495.
9. Hayes DM, Cvitkovic E, Golbey RB, et al. High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 1977; 39: 1372-1381. (Pubitemid 8108287)
10. Sculier JP, Klastersky J, Giner V, et al. Phase II randomized trial comparing high-dose cisplatin with moderate- dose cisplatin and carboplatin in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party. J Clin Oncol 1994; 12: 353-359.
11. Sculier JP, Lafitte JJ, Paesmans M, et al. Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer. Br J Cancer 2000; 83: 1128-1135.
12. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: Suppl. 1, S1-S266.
13. Launay-Vacher V, Oudard S, Janus N, et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 2007; 110: 1376-1384. (Pubitemid 47435612)
14. Máthé C, Bohács A, Duffek L, et al. Cisplatin nephrotoxicity aggravated by cardiovascular disease and diabetes in lung cancer patients. Eur Respir J 2011; 37: 888-894.
15. Ferguson MA, Vaidya VS, Bonventre JV. Biomarkers of nephrotoxic acute kidney injury. Toxicology 2008; 245: 182-193.
16. Waanders F, Navis G, van GH. Urinary tubular biomarkers of kidney damage: potential value in clinical practice. Am J Kidney Dis 2010; 55: 813-816.
17. Perico N, Cattaneo D, Remuzzi G. Kidney injury molecule 1: in search of biomarkers of chronic tubulointerstitial damage and disease progression. Am J Kidney Dis 2009; 53: 1-4.
18. Han WK, Wagener G, Zhu Y, et al. Urinary biomarkers in the early detection of acute kidney injury after cardiac surgery. Clin J Am Soc Nephrol 2009; 4: 873-882.
19. Kern EF, Erhard P, Sun W, et al. Early urinary markers of diabetic kidney disease: a nested case-control study from the Diabetes Control and Complications Trial (DCCT). Am J Kidney Dis 2010; 55: 824-834.